Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Healthcare Biotechnology
Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Liminal BioSciences Inc.
Bullboard Posts
User Avatar Image
(0)
•••
Post by OldYinon May 05, 2019 8:52am
142 Views
Post# 29711985

Press freedom

Press freedomHere is an excerpt of a letter I have sent to the Globe & Mail  asking for coverage of this story... we'll see if freedom of the press extends to biting the hand that feeds you.

"For example, a story which affects me directly, amongst thousands of other small  retail-investors, has been covered recently by a few outlets but not yet by the Globe. Here a few links:
 
https://www.journaldemontreal.com/2019/05/02/peter-thomson-prend-le-controle-de-prometic
 
https://business.financialpost.com/news/fp-street/dramatic-dilution-at-prometic-life-sciences-draws-ire-of-shareholders
 
https://seekingalpha.com/article/4254907-retail-investors-look-prometics-refinancing-plan
 
I hope this lack of coverage can be remedied, and that the Thomson family can yet be persuaded to direct its companies to act honourably in fairly treating investors who are being ruined by what they view as predatory business tactics."
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities